Summary:
A 6-Month, Randomized, Double-Blind, Placebo-controlled, Phase 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Obese Subjects with Type 2 Diabetes at Risk of Nonalcoholic Steatohepatitis
Criteria:- Be at least 18 years old
- Be diagnosed with Type 2 Diabetes
- Be overweight (BMI >30 kg/m2)
- Be treated with diet and exercise alone OR on stable metformin and/or SGLT2 (i.e. Brenzavvy, Invokana, Farxiga, Jardiance, Steglatro, etc.)
- Additional eligibility critetia apply
Qualified Participants May Receive:
Up to $6,305 for time and travel-related expenses